Vor Biopharma Inc. (VOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
VOR Stock Price Chart Interactive Chart >
VOR Price/Volume Stats
| Current price | $5.27 | 52-week high | $9.72 |
| Prev. close | $4.97 | 52-week low | $3.48 |
| Day low | $4.96 | Volume | 60,328 |
| Day high | $5.35 | Avg. volume | 101,986 |
| 50-day MA | $5.78 | Dividend yield | N/A |
| 200-day MA | $5.03 | Market Cap | 203.77M |
Vor Biopharma Inc. (VOR) Company Bio
Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.
Latest VOR News From Around the Web
Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem MeetingsCAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, tak |
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceCAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual Oncology Conference – Fireside ChatDate: Wednesday, January 18, 2023Time: 12:00 PM ET A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived repla |
Vor Biopharma Inc. Given Consensus Rating of “Moderate Buy” by AnalystsShares of Vor Biopharma Inc. have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has… |
12-Month Price Target For Vor Biopharma Inc. (NASDAQ:VOR) Now Sits At $38.00In last trading session, Vor Biopharma Inc. (NASDAQ:VOR) saw 0.38 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $7.07 trading at -$0.09 or -1.26% at ring of the bell on the day assigns it a market valuation of $271.21M. That closing price of VOR’s stock is … 12-Month Price Target For Vor Biopharma Inc. (NASDAQ:VOR) Now Sits At $38.00 Read More » |
Bath & Body Works and Vor Biopharma Stock See Action From Activist InvestorsThird Point disclosed a larger stake in body- and personal-care retailer Bath & Body Works. RA Capital more than doubled its stake in pharmaceutical firm Vor Biopharma. |
VOR Price Returns
| 1-mo | -20.75% |
| 3-mo | 14.57% |
| 6-mo | 4.56% |
| 1-year | -36.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -20.75% |
| 2022 | -42.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...